NUCLEUS SPECIALITY PHARMA LLP

NUCLEUS SPECIALITY PHARMA LLP (CIN: ABC-1401) is a company incorporated on 19 Aug 2022. It is classified as a company and is registered at Registrar of Companies, ROC Mumbai. Its authorized share capital is Rs. NaN and its paid-up capital is Rs. NaN.
NUCLEUS SPECIALITY PHARMA LLP's Annual General Meeting (AGM) was last held on N/A and, as per records from the Ministry of Corporate Affairs (MCA), its balance sheet was last filed on N/A.
NUCLEUS SPECIALITY PHARMA LLP's NIC code is . As per the NIC code, it is involved in 0.
The registered address of NUCLEUS SPECIALITY PHARMA LLP is A-603, GIRNAR TOWER, G D AMBEKAR MARG,AMBEWADI, KALACHOWKI, MUMBAI,Kalachowki,Mumbai,Mumbai,Maharashtra,India,400033.
Current status: Active.

Basic Information

CIN/LLPIN/FCRN:	ABC-1401
ROC Code:	ROC Mumbai
Company Class:	No Data Available
Company Category:	No Data Available
Activity Description:	0
Active Compliance:	No Data Available

Annual Compliance Status

Date of Inc.:	08/19/2022
Date of AGM:	No Data Available
Date of B/S:	No Data Available
Company Status:	Active
Industry:	No Data Available
Registered address:	A-603, GIRNAR TOWER, G D AMBEKAR MARG,AMBEWADI, KALACHOWKI, MUMBAI,Kalachowki,Mumbai,Mumbai,Maharashtra,India,400033

Key Numbers

Authorised Capital:	No Data Available
Paid up Capital:	No Data Available
Listing Status:	Unlisted
Filing status:	No Data Available
NIC Code:	No Data Available

Previous Name

Previous Company Name:

NUCLEUS SPECIALITY PHARMA LLP

Previous CIN

Previous CIN:

ABC-1401

Regulatory Filings for NUCLEUS SPECIALITY PHARMA LLP

In India, every company must submit a variety of documents such as financial statements, loan contracts, shareholder lists, director details, funding rounds, and more. These documents provide reliable and valuable insights into a company's operations. However, going through them to assess a company's standing can be an overwhelming and time-consuming task.

Our reports are crafted to help you save valuable time by highlighting essential information and organizing it in a way that simplifies your research process.

Grasping the critical insights from our reports can be vital for anyone involved with NUCLEUS SPECIALITY PHARMA LLP, whether you’re a customer, vendor, investor, partner, or even a prospective employee.

Access the complete report for NUCLEUS SPECIALITY PHARMA LLP

Litigation Report for NUCLEUS SPECIALITY PHARMA LLP

Obtain a detailed list of all legal cases that NUCLEUS SPECIALITY PHARMA LLP is currently involved in or has been part of in the past. The litigation search report is essential for anyone considering working with NUCLEUS SPECIALITY PHARMA LLP, whether as a vendor, employee, or customer. It provides crucial information about the legal risks associated with doing business with NUCLEUS SPECIALITY PHARMA LLP and its directors.

Our search encompasses both civil and criminal cases, covering over 670 courts and institutions, including the Supreme Court, High Courts, District Courts, Tribunals, and more. Click here to explore the full list of covered courts and organizations.

Access the full Litigation Search Report for NUCLEUS SPECIALITY PHARMA LLP

Outstanding Payments to Micro & Small Enterprises

It is mandatory for companies to submit bi-annual returns detailing payments owed to Micro & Small Enterprises that are overdue by more than 45 days. This data is essential for assessing whether NUCLEUS SPECIALITY PHARMA LLP makes timely payments to its suppliers. Analyzing this information over time can reveal whether the company has been delaying payments to its smaller vendors. Such details are only accessible if the company has filed its bi-annual returns with the Registrar of Companies.

Filing Type	As On	Amount Due to MSME	Current Liabilities	Ratio to Current Liabilities	Reasons for Delay

Investor Complaints & Serious Complaints About NUCLEUS SPECIALITY PHARMA LLP

This section provides information on investor or serious complaints lodged with the Registrar of Companies. Such data can help identify possible warning signs or concerns regarding the company.

Director Complaints

Date	DIN	Cessation Date	Cessation Reason	Complaint

Serious Complaints

Date	Complaint	Other Details

Investor Complaints & Other Complaints

Date	Complaint Type	Complaint Sub Type	Particulars of Securities	Period	Complaint	Other Details

Directors
DIN	Name	Role	Appointment Date
06804790	MAHENDRA HUKUMSINGH RAJPUROHIT	Designated Partner	2022-08-19
10016184	SANDEEP UDAYPRATAP SINGH	Designated Partner	2022-08-19
10016185	KISHORE ATMARAM WADEKAR	Designated Partner	2022-08-19

Charges
Charge ID	Status	Date of Creation	Date of Satisfaction
No Data Available

Prosecution Details of NUCLEUS SPECIALITY PHARMA LLP
S.No.	Defaulting Entities	Court Name	Prosecution Section	Date of Order	Status

Balance Sheet

Financial data is accessible only if the company has submitted its filings. In the absence of filed returns, financial details for the respective period will not be provided.

Category	2024-03-31	2023-03-31	2022-03-31	2021-03-31	2020-03-31	2019-03-31	2018-03-31
Equity and Liabilities
Shareholder's Funds
Share Capital
Reserves & Surplus
Money Received Against Share Warrants
Share Application Money Pending Allotment
Non-current Liabilities
Long-term Borrowings
Deferred Tax Liabilities
Other Long Term Liabilities
Long Term Provisions
Current Liabilities
Short-term Borrowings
Trade Payables
Other Current Liabilities
Short Term Provisions
Total Equity and Liabilities
Assets
Non-current Assets
Fixed Assets
Tangible Assets
Intangible Assets
Capital Work In Progress
Intangible Assets Under Development
Non-current Investments
Deferred Tax Assets (net)
Long-term Loans & Advances
Other Non-current Assets
Current Assets
Current Investments
Inventories
Trade Receivables
Cash & Cash Equivalents
Short-term Loans & Advances
Other Current Assets
Total Assets

Profit & Loss Statement of NUCLEUS SPECIALITY PHARMA LLP
Financial data is accessible only if the company has submitted its filings. If the company has not filed its returns, financial information for the corresponding period will not be available.
Category	2024	2023	2022	2021	2020	2019	2018
Download Audited Financials
REVENUE FROM OPERATIONS
Domestic Turnover
Sale of Goods Manufactured
Sale of Goods Traded
Sale of Supply of Services
Export Turnover
Sale of Goods Manufactured
Sale of Goods Traded
Sale or Supply of Services
Other Income
Total Revenue from Operations
EXPENSES
Cost of Materials Consumed
Purchases of Stock in Trade
Change in Inventories of
Finished Goods
Work in Progress
Stock in Trade
Employee Benefit Expenses
Managerial Remuneration
Payment to Auditors
Insurance Expenses
Power & Fuel
Finance Cost
Depreciation & Amortization Expenses
Other Expenses
Total Expenses
Profit before Exceptional Items, Extraordinary Items and Tax
Exceptional Items
Profit before Extraordinary Items and Tax
Extraordinary Items
Profit before Tax
Tax Expense
Current Tax
Deferred Tax
Profit/Loss after Tax from Continuing Operations
Profit/Loss after Tax from Discontinuing Operations
Tax Expense of Discontinuing Operations
Total Profit/Loss
Earnings per Equity Share (EPS) before Extraordinary Items
Basic
Diluted
Earnings per Equity Share (EPS) after Extraordinary Items
Basic
Diluted

Fund Raising Activity of NUCLEUS SPECIALITY PHARMA LLP

This section provides information on the cash raised through the allocation of equity or debentures, including funds raised via Venture Capital. Additional details, such as investor names, are available in the attachments. This data is accessible only if the company has raised funds through the cash allotment of equity or debentures.

Date of Allotment	Securities Alloted	Terms	Number of Securities	Nominal Amount	Premium Amount Due & Payable	Premium Amount Paid	Total Discount	Amount to be Paid on Calls (Excluding Premium)	Attachments

Subsidiaries, Associate Companies & Joint Ventures of NUCLEUS SPECIALITY PHARMA LLP

This section provides a list of the company's associate companies and joint ventures based on the latest available annual returns. If the company has not filed annual returns or does not have any subsidiaries or joint ventures, this information will not be available.

Company Identifier	Name	Percentage of Shares Held

Board Meetings of NUCLEUS SPECIALITY PHARMA LLP

This section provides a list of board resolutions submitted by the company to the Registrar of Companies.

Date of Filing	Date of Dispatch of Notice	Date of Passing Resolution	Section (Companies Act 2013)	Section (Companies Act 1956)	Subject Matter of Resolution	Resolution Agreed By	Resolution Type	Additional Documents

Contact Details of NUCLEUS SPECIALITY PHARMA LLP

Email ID:	No Data Available
Website:	Not Available
Address:	A-603, GIRNAR TOWER, G D AMBEKAR MARG,AMBEWADI, KALACHOWKI, MUMBAI,Kalachowki,Mumbai,Mumbai,Maharashtra,India,400033

Auditors of NUCLEUS SPECIALITY PHARMA LLP

This section provides details of the auditors associated with the company over the years. Such information is accessible only if the company has submitted its annual returns to the Registrar of Companies.

Financial Year	Name of Auditor or Firm	PAN of Auditor or Firm	Membership Number / Registration Number	Name of Auditor Signing Report	Membership Number of Auditor Signing Report

View this company on

Finanvo Technowire